Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.
In 2009 was created OUP (Osage University Partners), which is appeared as VC. The main office of represented VC is situated in the Bala Cynwyd. The fund was located in North America if to be more exact in United States.
Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. We can highlight the next thriving fund investment areas, such as Biotechnology, Artificial Intelligence. The fund has no exact preference in some founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the most popular portfolio startups of the fund, we may highlight Receptos, Cardioxyl Pharmaceuticals, Guardant Health.
This organization was formed by Robert Adelson. We also calculated 5 valuable employees in our database.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The top amount of exits for fund were in 2017. The real fund results show that this VC is 16 percentage points less often commits exit comparing to other companies. The typical startup value when the investment from OUP (Osage University Partners) is 50-100 millions dollars. The fund is constantly included in 7-12 deals per year. The top activity for fund was in 2018. Despite it in 2019 the fund had an activity. Opposing the other organizations, this OUP (Osage University Partners) works on 9 percentage points less the average amount of lead investments.
The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the OUP (Osage University Partners), startups are often financed by OrbiMed, BioAdvance, Sutter Hill Ventures. The meaningful sponsors for the fund in investment in the same round are Sutter Hill Ventures, The Column Group, HBM Healthcare Investments AG. In the next rounds fund is usually obtained by General Catalyst, Lux Capital, OrbiMed.
Related Funds
Funds with similar focus
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Normunity | $65M | 25 Oct 2022 | West Haven, Connecticut, United States | ||
Metalenz | $30M | 05 Oct 2022 | Boston, Massachusetts, United States | ||
Delfi Diagnostics | $225M | 18 Jul 2022 | Baltimore, Maryland, United States | ||
Nikola Labs Inc. | $9M | 27 Jun 2022 | Ohio, United States | ||
MicroTransponder | $73M | 20 Jun 2022 | Dallas, Texas, United States | ||
Brimstone Energy | $55M | 24 Mar 2022 | Berkeley, California, United States | ||
Antiva Biosciences | $31M | 02 Nov 2021 | California, United States | ||
ReCode Therapeutics | $80M | 21 Oct 2021 | Dallas, Texas, United States | ||
Vanqua Bio | $85M | 14 Sep 2021 | Chicago, Illinois, United States |
– ReCode Therapeutics announced the closing of an $80m Series B financing round co-led by Pfizer Ventures and EcoR1 Capital.
– The round was led by Pfizer Ventures and EcoR1 Capital.
– New investors include Sanofi Ventures, funds managed by Tekla Capital Management, Superstring Capital and NS Investment.
– Existing investors who participated included OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, and Osage University Partners.
– DiCE Molecules, a biopharmaceutical company leveraging its proprietary DNA-encoded library platform to discover and develop next-generation therapeutics in immunology and other therapeutic areas, announced the completion of its $60 million Series C-1 financing.
– The financing was led by RA Capital Management and Sands Capital, with participation from new investors Janus Henderson Investors, Deep Track Capital and Logos Capital.
– Existing investors Northpond Ventures, Eventide Asset Management, Driehaus Capital Management, Soleus Capital, New Leaf Venture Partners, Osage University Partners and Asymmetry Capital Management also participated in the round.
– With the closing of this Series C-1 financing round, the Company has raised approximately $200 million to date.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data 
Get matched with relevant funds
